TME Pharma N.V. ALTME
EURONEXT · Frankreich · Gesundheitstechnologie
€0,1034-0,00 (-0,77 %)
Markt geschlossen· · EUR · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Markt geschlossen· · EUR · Daten können verzögert sein
Kurse können verzögert sein und dienen nur zu Informationszwecken - keine Anlageberatung.
Gesamtrendite inklusive Dividenden.
Wo der Kurs im Verhältnis zu seinen 50- und 200-Tage-Durchschnitten steht.
Makkler Fair Value, Finanzgesundheit, Analystenmeinung, Vergleichsunternehmen und MakklerAI.
TME PHARMA CEO MESSAGE Berlin, Germany, September 16, 2026, 8.00am CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for brain cancer and eye diseases, today publishes a message from its CEO for the shareholders. Dear Shareholders,As I look back on the recent period, one clear feeling dominates: remained confidence in the path we are taking. We fully understand that many of you are eager to see concrete
TME Pharma provides update on its activities TME Pharma enters the final evaluation phase of advanced discussions with two potential partners for a license agreement.Discussions and potential partnership are aimed at enabling the further development of the phase2-development of flagship product NOX-A12.NOX-A12 holds FDA and EU Orphan Drug and FDA Fast Track designations in glioblastoma, supported by recent peer-reviewed publication in Nature Communications.With estimated yearly peak sales potent
Minutes of the TME Pharma Annual General Meeting Berlin, Germany, June 17, 2026, 6:30 p.m. CET – TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company specializing in the development of novel therapies for brain cancer and eye diseases, today announced that all resolutions were adopted at the meeting held on June 15. The Annual General Meeting of TME Pharma shareholders was held on Monday, June 15, 2026, chaired by Mr. Diede van den Ouden. Four shareholders were
Aktuelle Schlagzeilen Dritter zu diesem Unternehmen, getrennt von Makklers eigener Redaktion und mit Verlinkung zum Herausgeber. Für die Richtigkeit ist der jeweilige Herausgeber verantwortlich.